Keri Urwin brings over 20 years of experience in clinical trial management leading large, global teams through many phase I-IV projects from study start through regulatory submission. Using her ability to see the “big picture,” Keri resolves issues quickly to bring vendors and cross-functional teams together. She enjoys acting in leadership capacities as Head of Clinical Operations but also enjoys project management, performing Gap Analyses, and participating in organizational development projects. She has therapeutic experience in neurology, pain management, PE/DVT, sexual dysfunction, CHF, gene therapy, and oncology.
Before joining Halloran, Keri spent six years working as a consultant for Pfizer on pain management and PE/DVT trials. She also spent two years at GlaxoSmithKline where she was a lead study manager assigned to various global trials focusing on restless leg syndrome and MS. Earlier in her career, Keri spent five years at Biogen Idec where she focused on multiple sclerosis (MS) trials for Avonex and Tysabri and was part of the submission team responsible for FDA approval of Tysabri.
Keri earned a Master of Business Administration from Meredith College in Raleigh, NC and a Bachelor of Arts in psychology from the University of Iowa.